Medipal Holdings Corporation changed its net income forecast for the fiscal year ending March 2027 from ¥43.0 billion to ¥53.0 billion. The share buyback is capped at 4 million shares or ¥10.0 billion, will run from 6 November to 31 March next year, and all acquired shares will be cancelled.
According to the latest full-year outlook disclosed after the close of trading, Medipal Holdings Corporation changed its consolidated net income forecast for the fiscal year ending March 2027 from ¥43.0 billion to ¥53.0 billion. The company cited gains on the sale of investment securities arising from the reduction of strategic shareholdings as a factor boosting profit. Net sales were left unchanged at ¥3.944 trillion, while operating income remained at the previous forecast level of ¥53.5 billion.
For the share buyback, the acquisition limit was set at 4 million shares, equivalent to 1.95% of shares outstanding, or ¥10.0 billion. The acquisition period was set from 6 November to 31 March next year, and all acquired shares are to be cancelled.
The announcement was made through formal disclosure to the market, and it remains undecided whether any additional information will be disclosed. Investors will need to monitor developments in the company’s capital allocation and the impact of gains from the sale of investment securities.
Overall, the upward revision to the net income forecast and the share buyback can be viewed as moves indicating the framework for financial stability and shareholder returns. The progress of the figures is expected to be reassessed based on future earnings briefings and additional disclosures.